Insider Transactions in Q1 2023 at Collegium Pharmaceutical, Inc (COLL)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2023
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
31,640
-23.08%
|
$727,720
$23.77 P/Share
|
|
Mar 01
2023
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,324
-8.99%
|
$346,424
$26.7 P/Share
|
|
Feb 13
2023
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
11,250
-2.74%
|
$292,500
$26.88 P/Share
|
|
Feb 13
2023
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+2.66%
|
$168,750
$15.9 P/Share
|
|
Feb 13
2023
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
21,811
-13.69%
|
$567,086
$26.88 P/Share
|
|
Feb 10
2023
|
Thomas B Smith EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,185
+50.0%
|
-
|
|
Feb 10
2023
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
21,326
-6.48%
|
$554,476
$26.75 P/Share
|
|
Feb 10
2023
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,734
+17.42%
|
-
|
|
Feb 10
2023
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
103,857
-10.87%
|
$2,700,282
$26.75 P/Share
|
|
Feb 10
2023
|
Joseph Ciaffoni President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
255,194
+22.87%
|
-
|
|
Feb 10
2023
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,854
-3.73%
|
$282,204
$26.75 P/Share
|
|
Feb 10
2023
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,610
+16.4%
|
-
|
|
Feb 10
2023
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
24,046
-6.76%
|
$625,196
$26.75 P/Share
|
|
Feb 10
2023
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
73,864
+17.85%
|
-
|
|
Jan 09
2023
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,834
-5.12%
|
$481,518
$27.83 P/Share
|